Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended anticoagulation in cancer-associated VTE: LMWH versus VKA
NL-OMON39493Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of low molecular weight heparin calcium in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Symptomatic recurrent venous thromboembolism and Major bleeding. Started Jan 2010; status: active, not recruiting.
02
Drugs
low molecular weight heparin calcium
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON39493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39493.